P237 Annual incidence and prevalence of ulcerative colitis and Crohn’s disease from 2010 to 2017 in four Nordic countries: Results from the TRINordic study
M. Lördal1, J. Burisch2, E. Langholz3, T. Knudsen4,5, M. Voutilainen6, B. Moum7, B. Saebo8, H. Paula9, C. Malmgren10, M. Coskun11, H.O. Melberg12
1Department of Gastroenterology and Hepatology, Danderyds Hospital, Stockholm, Sweden, 2Gastrounit- Medical Division, Hvidovre University Hospital, Hvidovre, Denmark, 3Department of Medical Gastroenterology, Herlev Hospital, Herlev, Denmark, 4Department of Regional Health Research, University of Southern Denmark, O dense, Denmark, 5Department of Medicine, Hospital South West Denmark, Odense, Denmark, 6Department of Gastroenterology, University of Turku, Turku, Finland, 7Department of Gastroenterology, Oslo University Hospital, Oslo, Norway, 8Takeda AS, Medical Affairs, Asker, Norway, 9Takeda Oy, Medical Affairs, Helsinki, Finland, 10Takeda Pharma AB, Medical Affairs, Stockholm, Sweden, 11Takeda Pharma A/S, Medical Affairs, Taastrup, Denmark, 12Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway
Incidence and prevalence of inflammatory bowel diseases (IBD) have been increasing for the past decades in the western world, however with an emerging trend of incidence stabilisation in recent years. There is an indication of higher IBD incidence and prevalence in northern Europe, especially in the Nordic region, compared with southern Europe.
This retrospective observational study collected data from the National Patient Registries and National Prescription Registries (Sweden [SWE], Norway [NOR], Denmark [DEN]) and one university hospital database (Turku, Finland [FIN]) during 2010–2017 to investigate the annual incidence and prevalence of ulcerative colitis (UC) and Crohn’s disease (CD). Patients with ≥2 ICD-10 diagnosis codes for UC (K51) or CD (K50) from 2010 or later and no K51 or K50 codes prior to 2010 were included; patients were classified according to their last code. The look-back period for SWE was until 2000, for NOR until 2008, for DEN until 1995, and for FIN until 2004. Incidence proportions highlight results through 2016, as 2017 patients had less than 1-year follow-up.
In total, 69,876 patients were included (SWE
This retrospective observational study showed that during 2016, the annual incidence of UC ranged from 25–44 patients per 100,000 persons across the evaluated Nordic countries, whereas the annual incidence of CD was 16–22 patients per 100,000 persons. Prevalence of both UC and CD increased during 2010–2017 in all four countries. Estimates of UC and CD incidence and prevalence in this analysis are greater than reported in the published literature. Additional analyses are underway to further explore the impact of methodological decisions on the estimates of UC and CD annual incidence and prevalence.